File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Early Treatment of High-Risk Hospitalized Coronavirus Disease 2019 (COVID-19) Patients With a Combination of Interferon Beta-1b and Remdesivir: A Phase 2 Open-label Randomized Controlled Trial

TitleEarly Treatment of High-Risk Hospitalized Coronavirus Disease 2019 (COVID-19) Patients With a Combination of Interferon Beta-1b and Remdesivir: A Phase 2 Open-label Randomized Controlled Trial
Authors
Tam, ARZhang, RLung, KCLiu, RLeung, KYLiu, DFan, YLu, LLam, AHYChung, WHTYip, CYLo, JWu, AKLLee, RSin, SNg, PYChan, WMShum, HPYan, WWChan, JFWCheng, CCVLau, WCSTo, KKWChan, KHYuen, KYHung, FNI
Issue Date2022
Citation
Clinical Infectious Diseases, 2022 How to Cite?
DOI: http://dx.doi.org/10.1093/cid/ciac523
Persistent Identifierhttp://hdl.handle.net/10722/317392
ISI Accession Number ID
WOS:000833489900001

 

DC FieldValueLanguage
dc.contributor.authorTam, AR-
dc.contributor.authorZhang, R-
dc.contributor.authorLung, KC-
dc.contributor.authorLiu, R-
dc.contributor.authorLeung, KY-
dc.contributor.authorLiu, D-
dc.contributor.authorFan, Y-
dc.contributor.authorLu, L-
dc.contributor.authorLam, AHY-
dc.contributor.authorChung, WHT-
dc.contributor.authorYip, CY-
dc.contributor.authorLo, J-
dc.contributor.authorWu, AKL-
dc.contributor.authorLee, R-
dc.contributor.authorSin, S-
dc.contributor.authorNg, PY-
dc.contributor.authorChan, WM-
dc.contributor.authorShum, HP-
dc.contributor.authorYan, WW-
dc.contributor.authorChan, JFW-
dc.contributor.authorCheng, CCV-
dc.contributor.authorLau, WCS-
dc.contributor.authorTo, KKW-
dc.contributor.authorChan, KH-
dc.contributor.authorYuen, KY-
dc.contributor.authorHung, FNI-
dc.date.accessioned2022-10-07T10:19:41Z-
dc.date.available2022-10-07T10:19:41Z-
dc.date.issued2022-
dc.identifier.citationClinical Infectious Diseases, 2022-
dc.identifier.urihttp://hdl.handle.net/10722/317392-
dc.languageeng-
dc.relation.ispartofClinical Infectious Diseases-
dc.titleEarly Treatment of High-Risk Hospitalized Coronavirus Disease 2019 (COVID-19) Patients With a Combination of Interferon Beta-1b and Remdesivir: A Phase 2 Open-label Randomized Controlled Trial-
dc.typeArticle-
dc.identifier.emailZhang, R: zhangrq@hku.hk-
dc.identifier.emailYip, CY: yipcyril@hku.hk-
dc.identifier.emailChan, JFW: jfwchan@hku.hk-
dc.identifier.emailLau, WCS: cslau@hku.hk-
dc.identifier.emailTo, KKW: kelvinto@hku.hk-
dc.identifier.emailYuen, KY: kyyuen@hkucc.hku.hk-
dc.identifier.emailHung, FNI: ivanhung@hkucc.hku.hk-
dc.identifier.authorityYip, CY=rp01721-
dc.identifier.authorityChan, JFW=rp01736-
dc.identifier.authorityLau, WCS=rp01348-
dc.identifier.authorityTo, KKW=rp01384-
dc.identifier.authorityChan, KH=rp01921-
dc.identifier.authorityYuen, KY=rp00366-
dc.identifier.authorityHung, FNI=rp00508-
dc.identifier.doi10.1093/cid/ciac523-
dc.identifier.hkuros337001-
dc.identifier.isiWOS:000833489900001-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats